2025-07-07, Mon.

Top Stories       Business       Culture & Life       Science & Technology       World

Lecture

Notification

 

NEWS > Science & Technology


Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges

Date: 2025-07-05

SYDNEY -- As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class.

LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain.

According to Novotech’s analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities.

Highlights from the report include:

· A growing pipeline of preclinical and Phase I-II LBP candidates, with notable concentration in Alzheimer’s, IBD, diabetes, and NASH.
· Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation.
· North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific.
· A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030.

The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023.

With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution.

Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success.



 to the Top List of News

Kioxia Unveils 8th Gen BiCS Flash SSDs to Boost AI And HPC GPU Efficiency
Faraday Delivers Latest SerDes IP to Complete Interface Lineup on UMC¡¯s 22nm Platform
LG Launches Upgraded webOS Hub With Advanced AI Solutions for Third-Party Brands
Lenovo Named a Major Player in IDC MarketScape for Hybrid IT Infrastructure Consulting and Integration Services
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
Lenovo Unveils New Generation of AI PC Desktops and Monitors Designed to Maximize Productivity and Multitasking
Yokogawa Collaborates with Shell on Robotics and AI Technology for Plant Maintenance

 

NetApp Appoints Disruptive Innovator Syam Nair as Chief Product Office...
NetApp Report Highlights Fierce Competition in Global AI Leadership
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
Cirium Introduces First AI-Powered Solution for On-Time Performance An...
BeOne Medicines Launches Following Redomiciliation to Switzerland, Mar...
Experian Accelerates Migration to AWS to Drive Innovation with Generat...
LG 2025 OLED TVs Achieve ¡°True Visual Experience with Indoor Lighting...
Toshiba Releases 2-Channel Automotive Standard Digital Isolators Compl...
LTIMindtree Launches ¡®BlueVerse¡¯ - An AI Ecosystem that will Define ...
Cargill Earns #1 Global Ranking for Removing Trans Fats From Edible Oi...

 

 

60, Gamasanro 27gil, Guro-gu, Seoul, Korea, e-mail: news@newsji.com

Copyright, NEWSJI NETWORK.